Our Journey Our Journey to Market Launch

  • 2012
    £100K TSB Grant
    / Feasibility study to test miniaturisation.
  • 2015
    Investments Received
    / £150K Angel Investment / £120 IUK SMART / £132K Director Investment / Development & testing of optical device.
  • 2016
    £100K SBRI
    / End user feasibility feedback & testing.
  • 2017
    £150K NIHR i4i Connect
    / Further development & testing / Next level development higher TRL and data.
  • 2020
    New Company Formed
    / £75K COVID Grant / Using same device to test COVID samples with new parameters.
  • 2022
    Investments Received
    / £80K application to High Growth Innovation Fund call / £400K IUK SMART / £175K Liverpool Ventures
  • 2022
    Product Developments
    / Optimising & testing higher TRL device with early data / New hand-held versions with new electronics and sensors.
  • 2022
    Total Investments Raised to Date
    £1.4M

who we want to work with Future Partners

The right partnerships are critical to our success, and we are looking to engage future partners now.

Hospitals

We are seeking hospitals to work with us for multi-centered clinical trials. 

Manufacturers

We are seeking partners to help us scale up manufacturing.

Diagnostic Companies

Partners operating in the diagnostic and partner diagnostic sectors.

Developing life-saving rapid diagnosis of Sepsis.

Address: 61 Rodney Street, Liverpool, England, L1 9ER
Phone: +44 (0)7814 976 875
Mail: info@frequasense.co.uk